CaMKII-based gene therapy protects retinal ganglion cells in a broad range of disease: ischemic retinopathy and congenital glaucoma

Key Points

• Retinal ganglion cells are better protected, demonstrating significant therapeutic effects from CamKII-based gene therapy.
• The gene therapy intervention improved neuronal survival, with effects observed across multiple disease conditions.
• This analysis involved cellular models reflecting ischemic retinopathy and congenital glaucoma, evaluating cell health over time.
• Findings suggest that CamKII-targeted therapies could enhance treatment strategies for various retinal diseases.